SCHEMBL5435692

SCHEMBL5435692

NC1CCCCC1C(=O)Nc1ccc(N2CCCOC2=O)cc1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 5/20 0.52
MAOA P21397 4/20 0.52
MAOB P27338 4/20 0.52
RCOR1 Q9UKL0 4/20 0.52
ALDH1A1 P00352 2/20 0.44
KDM1B Q8NB78 2/20 0.44
F10 P00742 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPT P10636 3/20 0.40
LMNA P02545 2/20 0.40
HTT P42858 2/20 0.40
RAB9A P51151 2/20 0.40
KDM4E B2RXH2 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
POLB P06746 1/20 0.40
GAA P10253 2/20 0.39
MEN1 O00255 1/20 0.38
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5442494 0.98 KDM1A (0.52) KDM1AMAOAMAOBRCOR1ALDH1A1
SCHEMBL5435689 0.90 GRM4 (0.46) KDM1AMAOAMAOBRCOR1ALDH1A1
SCHEMBL5442490 0.87 KDM1A (0.46) KDM1AMAOAMAOBRCOR1ALDH1A1
SCHEMBL5435864 0.82 F10 (0.57) ALDH1A1F10KMT2A
SCHEMBL5436044 0.81 F10 (0.41) KDM1AMAOAMAOBRCOR1ALDH1A1
SCHEMBL4745979 0.81 KDM1A (0.49) KDM1AMAOBALDH1A1F10KMT2A
SCHEMBL5445580 0.79 KLK5 (0.40) KDM1AMAOAMAOBRCOR1ALDH1A1
SCHEMBL5440980 0.79 KDM1A (0.49) KDM1AMAOBALDH1A1F10KMT2A
SCHEMBL4690375 0.77 MAPKAPK2 (0.46) KDM1AMAOAMAOBRCOR1ALDH1A1
SCHEMBL4742422 0.76 F10 (0.61) KDM1AMAOAMAOBRCOR1KDM1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070135428-A1 LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS QIAO JENNIFER X 2007-06-14 US disclosed
US-7205318-B2 Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135428-A1 LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS F12, F2, PEPD KDM1A 2307/4885MAOA 753/4885MAOB 484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.